Promising Stem Cell Research Driving Industry's Growth in 2012
09 November 2012 - 12:20AM
Marketwired
Stem cell stocks have been gaining popularity among investors in
2012 as new and promising research continues to propel the industry
forward. A study performed earlier this year at Johns Hopkins
University has shown that stem cells from patients' own cardiac
tissue can be used to heal scarred tissue after a heart attack.
Five Star Equities examines the outlook for companies in the
Biotechnology Industry and provides equity research on Aastrom
Biosciences, Inc. (NASDAQ: ASTM) and Neostem Inc. (NYSE: NBS).
Access to the full company reports can be found at:
www.FiveStarEquities.com/ASTM
www.FiveStarEquities.com/NBS
A more recent study, also conducted at Johns Hopkins University,
has showed that stem cells donated by strangers were as safe and as
effective as the patient's own cells in repairing heart tissue.
This is a key advancement for the treatment of heart attack with
stem cells, as this possibly means stem cells could be stored for
use just as blood is now.
"You could have the cells ready to go in the blood bank so when
the patient comes in for a therapy -- there's no delay," said Dr.
Joshua Hare of the University of Miami. "It's also cheaper to make
the donor cells," as marrow from a single donor could provide
enough cells for the treatment of up to 10 people.
Five Star Equities releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.FiveStarEquities.com
and get exclusive access to our numerous stock reports and industry
newsletters.
Aastrom Biosciences is a leader in the development of
patient-specific multicellular therapies for the treatment of
severe, chronic cardiovascular diseases. Stem cell therapy is the
infusion, injection or transplantation of whole cells into a
patient for the treatment of a disease or condition.
NeoStem is a provider of adult stem cell collection, processing
and storage services in the United States, enabling healthy
individuals to donate and store their stem cells for personal
therapeutic use. In addition, the company collects and stores cord
blood cells of newborns which help to ensure a supply of autologous
stem cells for the child should they be needed for future medical
treatment.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024